CDMO partnership is your rocket fuel for innovation

The pharmaceutical landscape is evolving at an extraordinary pace. The global active pharmaceutical ingredient (API) market is expected to grow from $255 billion in 2024 to $359.4 billion by 2030, at a compound annual growth rate (CAGR) of 5.8% [1]. This growth is fueled by increasing demand for complex molecules and biologics. Therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists for diabetes and obesity, peptide-based drugs, and antibody-drug conjugates (ADCs) are redefining what API manufacturing looks like [2].

These scientific advances offer enormous potential for patients. But for the pharma companies making these medicines, they also introduce new levels of technical complexity, regulatory scrutiny, and pressure to deliver at speed.

Meeting these challenges requires more than manufacturing excellence. It calls for a new kind of CDMO partnership that is grounded in collaboration, flexibility, and continuous investment in capabilities.

GLP-1s, peptides, and ADCs are pushing manufacturing requirements into new territory. These molecules often demand high-potency containment, specialized purification technologies, precise process control, and dedicated expertise. At the same time, tighter timelines and growing regulatory demands leave little room for error. Development cycles are shorter, margins are slimmer, and the cost of a delay is higher than ever.

Many organizations are also feeling the strain of a widening knowledge gap. As modalities grow more complex, internal teams often lack hands-on experience with newer platforms or scale-up processes. That gap is putting greater pressure on external partners to deliver both technical guidance and reliable execution.

Not all CDMOs are equipped to operate at this level of complexity. Even technically sound partners can slow progress when communication breaks down or workflows are rigid. Delayed responses, unclear ownership, and siloed teams create friction where there should be momentum.

This is why drug developers are reevaluating what they need from a CDMO. Capability matters. But so does how that capability is delivered. The best partners are easy to work with, transparent about risks, and flexible enough to adapt when plans change. These qualities are especially critical in fast-moving modalities like ADCs, where alignment across teams, sites, and timelines is non-negotiable.

Supporting the next generation of therapies takes more than equipment upgrades. It takes sustained investment in infrastructure, people, and systems that can scale with science.

Across the industry, leading CDMOs are adopting advanced platforms like high-performance liquid chromatography (HPLC), expanding high-containment capacity, and integrating greener chemistries such as electrochemical synthesis. But the real differentiator lies in how these capabilities are brought together — through coordinated teams, streamlined tech transfers, and proactive project management.

Drug developers are actively seeking a CDMO partner who can reliably navigate complexity, demanding seamless technical integration and flexible, transparent project management to prevent costly delays. They need assurance that their complex, sensitive programs will be delivered reliably and on time.

At Axplora, we’ve designed our model around exactly the kind of partnership today’s programs demand. We operate a network of five manufacturing sites across Europe, giving customers scalable access to critical technologies, scientific expertise, and production capacity.

Our capabilities span advanced purification methods such as high-performance liquid chromatography (HPLC) and continuous chromatography, as well as high-potency API production — including ADC production and hazardous chemistry — and electrochemistry. We currently operate the largest pharmaceutical HPLC and continuous chromatography facility in the world.

Projects are matched to the most suitable site based on modality, timeline, and regulatory needs. Our teams are integrated early to reduce friction, streamline tech transfers, and solve challenges proactively. We align internally across technical and operational functions to ensure delivery is reliable and efficient.

This way of working has made us a trusted CDMO partner in some of the most demanding areas of API manufacturing. Today, Axplora is a key supplier to nearly 50 percent of all FDA-approved ADCs — a reflection of both our technical depth and our ability to collaborate effectively with leading innovators.

In a market where complexity is the norm, we work to make progress simpler, helping pharma companies stay ahead of scientific, operational, and regulatory change.

Ready to explore new frontiers of API innovation? Contact us and let’s pioneer what’s next, together.